Alnylam Pharmaceuticals Inc (DUL.SG)
Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
At close: 07:02PM CEST
| Previous close | 143.55 |
| Open | 140.70 |
| Bid | 139.05 x 100000 |
| Ask | 139.65 x 50000 |
| Day's range | 138.95 - 140.70 |
| 52-week range | 131.55 - 195.80 |
| Volume | |
| Avg. volume | 7 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.The Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) just released its latest first-quarter results and things are looking...
Insider MonkeyAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q1 2024 Earnings Call Transcript May 2, 2024 Alnylam Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.52272, expectations were $-0.75. ALNY isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for […]
ZacksAlnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y
Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings and revenues beat estimates, primarily driven by strong Amvuttra sales.
© 2024 Yahoo. All rights reserved.